Apatinib as an alternative therapy for advanced hepatocellular carcinoma

doi:10.4254/wjh.v12.i10.766

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5466)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

229

WORD

HTML

3293

Figures (1-1)

354

Sum=3955

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

610

Download

901

Sum=1511

Oct 27, 2020 (publication date) through Dec 20, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Oct 27, 2020; 12(10): 766-774
Published online Oct 27, 2020. doi: 10.4254/wjh.v12.i10.766

Open in New Tab Full Size Figure Download Figure

Figure 1 Schematic illustration of the mechanism of apatinib as an inhibitor of vascular endothelial growth factor receptor 2. VEGFR2: Vascular endothelial growth factor receptor 2.

Citation: Zhang XH, Cao MQ, Li XX, Zhang T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol 2020; 12(10): 766-774
URL: https://www.wjgnet.com/1948-5182/full/v12/i10/766.htm
DOI: https://dx.doi.org/10.4254/wjh.v12.i10.766